Takeda plans new r&d centre

Published: 7-Dec-2006
Sustainability

Japanese company Takeda Pharmaceutical is to spend ¥70-80bn to build a research and development centre in Kanagawa Prefecture, southwest of Tokyo, which will consolidate three domestic r&d centres.


Japanese company Takeda Pharmaceutical is to spend ¥70-80bn to build a research and development centre in Kanagawa Prefecture, southwest of Tokyo, which will consolidate three domestic r&d centres.

Upon completion, the centre will have more than 1,000 researchers, becoming one of the largest such units in the domestic industry.

Initially, some functions of a laboratory in Osaka will be relocated to Fujisawa. This move will include some 600 researchers from the unit in charge of developing new drug candidate compounds into substances that can be used in clinical trials.

Other facilities in Osaka and Ibaraki Prefecture will also be transferred to the new centre.

See more

You may also like

Sustainability

Bayer Schering Pharma acquires preclinical anticancer programme from Nycomed

Read more
Bayer Schering Pharma is expanding its oncology pipeline with the acquisition of a preclinical oncology programme from Swiss pharma company Nycomed.

Trending Articles

  1. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  2. Ecolab and SCG sign MOU to enhance business competitiveness and drive ESG progress This 5-year MOU underscores how collaboration can turn sustainability commitments into measurable outcomes, accelerating the journey toward Net Zero while strengthening cross-industry competitiveness
  3. Gerresheimer improves Rating Result and is once again awarded EcoVadis Gold Gerresheimer, among the top 4% of all rated companies, whose rating reaches a new high with 78 out of 100 points, ranking among the top 1% of the industry underlines consistent implementation of the sustainability strategy
  4. Five API manufacturing trends you need to know in 2025 How technology, sustainability and innovation are redefining pharmaceutical production
  5. GEA raises guidance following strong H1 performance Revised forecast reflects improved margins, robust order intake and efficiency gains

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Sustainability

Bayer Schering Pharma acquires preclinical anticancer programme from Nycomed

<p>Bayer Schering Pharma is expanding its oncology pipeline with the acquisition of a preclinical oncology programme from Swiss pharma company Nycomed. </p>
Sustainability

Takeda establishes r&d subsidiary in US

<p>Leading Japanese drug company Takeda Pharmaceutical has established an r&d subsidiary in the US to concentrate on therapeutic antibodies. </p>
Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

New SOLAR CEMNEX analyser offers advanced compliance and connectivity features
Manufacturing

Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS

The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
Sustainability

Gerresheimer improves Rating Result and is once again awarded EcoVadis Gold

Gerresheimer, among the top 4% of all rated companies, whose rating reaches a new high with 78 out of 100 points, ranking among the top 1% of the industry underlines consistent implementation of the sustainability strategy
Sustainability

Ecolab and SCG sign MOU to enhance business competitiveness and drive ESG progress

This 5-year MOU underscores how collaboration can turn sustainability commitments into measurable outcomes, accelerating the journey toward Net Zero while strengthening cross-industry competitiveness
Sustainability

Piramal Pharma publishes FY2025 sustainability report, outlining performance and decarbonization glidepath

Piramal Pharma Limited has released its fourth annual Sustainability Report for the financial year 2025, under the theme ‘Innovating Responsibly. Growing Sustainably.’
Subscribe now